Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note released on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

Hoth Therapeutics Trading Down 0.9 %

HOTH stock opened at $1.07 on Tuesday. Hoth Therapeutics has a twelve month low of $0.58 and a twelve month high of $3.80. The company’s 50 day moving average is $1.14 and its two-hundred day moving average is $0.94. The stock has a market cap of $7.38 million, a P/E ratio of -0.81 and a beta of 0.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, equities research analysts predict that Hoth Therapeutics will post -1.36 earnings per share for the current year.

Hedge Funds Weigh In On Hoth Therapeutics

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC increased its holdings in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,946 shares of the company’s stock after acquiring an additional 13,038 shares during the quarter. Geode Capital Management LLC owned approximately 1.39% of Hoth Therapeutics worth $72,000 at the end of the most recent quarter. 7.08% of the stock is currently owned by institutional investors and hedge funds.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.